Skip to main content
. 2023 Jan 17;133(2):e165076. doi: 10.1172/JCI165076

Table 2. CSF and plasma drug exposure in patients given a single i.c.v. dose of 30, 100, or 300 mg tralesinidase alfa.

graphic file with name jci-133-165076-g087.jpg